3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Melanoma
11
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Sarcoma
2
Pancreatic Neoplasms
2
Carcinoma, Merkel Cell
2
Squamous Cell Carcinoma of Head and Neck
1
Peritoneal Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell, Cutaneous
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Hepatocellular
1
Carcinoma, Ductal, Breast
1
Carcinoma, Ductal
1
Carcinoma, Basal Cell
1
Advanced Non CNS Tumors
1
Adenocarcinoma
1
Interventions
Peripheral Blood Stem Cell Transplantation
32
fludarabine phosphate
29
Cyclophosphamide
26
Whole-Body Irradiation
21
Cyclosporine
20
Busulfan
20
Mycophenolic Acid
19
Tacrolimus
16
Antilymphocyte Serum
14
Methotrexate
13
romidepsin
12
Etoposide
12
Filgrastim
11
Melphalan
9
Psychiatric Rehabilitation
8
Methylprednisolone
8
Dexamethasone
8
Bexarotene
8
Vorinostat
7
Flow Cytometry
7
Therapeutics
6
Radiotherapy
6
Calcium Dobesilate
6
Brentuximab Vedotin
6
Bortezomib
6
Alemtuzumab
6
sargramostim
5
fludarabine
5
denileukin diftitox
5
Polymerase Chain Reaction
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, T-Cell, Cutaneous
×
talimogene laherparepvec
×
Clear all
NCT03458117
2022-03-18
20139157 T-VEC
University of Zurich
Phase 1
Completed
26 enrolled